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Abstract
Background: Although hematopoietic cell transplant (HCT) recipients are routinely exposed to classic risk factors for
Clostridium difficile infection (CDI), few studies have assessed CDI risk in these high-risk patients, and data are especially
lacking for pediatric HCT recipients. We aimed to determine incidence and risk factors for CDI in adult and pediatric
allogeneic HCT recipients.
Methods: CDI was defined as having diarrhea that tested positive for C. difficile via PCR, cytotoxin assay, or dual
enzyme immunoassays. We included all patients who received an allogeneic HCT from 2008 to 2012 at the Fred
Hutchinson Cancer Research Center; those <1 year old or with CDI within 8 weeks pre-HCT were excluded. Patients
were categorized by transplanting hospital (“adult” or “pediatric”) and followed for 100 days post-HCT.
Results: Of 1182 HCT recipients, CDI was diagnosed in 17 % (33/192) of pediatric recipients for an incidence of 20 per
10,000 patient-days, and 11 % (107/990) of adult recipients for an incidence of 12 per 10,000. Pediatric recipients were
diagnosed a median of 51 days (interquartile range [IQR]: 5, 72) after HCT and adults at 16 days (IQR= 5, 49).
Compared with calendar year 2008, pediatric recipients transplanted in 2012 were at increased risk for CDI (hazard
ratio [HR]= 3.99, p= .02). Myeloablative conditioning increased CDI risk in adult recipients (HR= 1.81, p= .005).
Conclusions: Pediatric and adult allogeneic recipients are at high risk of CDI post-HCT, particularly adult recipients of
myeloablative conditioning. Differences in CDI incidence between children and adults may have resulted from
exposure differences related to age; therefore, separately evaluating these groups should be considered in future CDI
studies.
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Background
Clostridium difficile infection (CDI) is the most com-
mon cause of nosocomial infectious diarrhea in the US
[1–5], resulting in substantial morbidity and mortality
among hospitalized patients. Costs associated with this
healthcare-associated pathogen, the emergence of hyper-
virulent strains of C. difficile, and reports of increasing
incidence and severity of CDI in both hospitals and in
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the community have led to major efforts to control and
prevent this infection [1–5].
Patients undergoing allogeneic hematopoietic cell trans-
plantation (HCT) typically experience one or more classic
CDI risk factors during their care, and have been shown to
be at increased risk for CDI when compared to both gen-
eral and other cancer patient populations [6]. However,
incidence estimates among allogeneic HCT recipients
have varied from 2–27 % [7–16]. Furthermore, the risk
imposed by factors exclusive to allogeneic HCT recipients,
such as acute graft-versus-host disease (GVHD) and con-
ditioning regimens, differ across studies [8–10, 15, 17].
It is unclear if differences in center-based transplant
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care, patient populations, or institutional testing strategies
contribute to this variance.
In addition, studies on CDI among allogeneic HCT
recipients have focused exclusively on adults or adult-
dominated cohorts, with minimal data presented
exclusively on CDI among pediatric HCT recipients. In
the general population, the burden of CDI in pediatric
patients is increasing, and the associated morbidity and
mortality often differs from adults [18–20]. Even among
pediatric patients, the risk of CDI varies by age: younger
children have a higher rate of CDI [19, 21]; infants have
a high risk of asymptomatic carriage of C. difficile and
may serve as a reservoir for infection [22–25]. CDI data
in pediatric HCT recipients have not been well described.
Given the variance in results across studies and the need
for additional pediatric data, we examined the incidence
and risk factors of CDI among two cohorts of allogeneic
HCT recipients at a large cancer center.
Methods
Study design and population
We extracted demographic and medical data from a
prospectively collected database on pediatric and adult
HCT recipients from 56 days (8 weeks) pre-HCT through
100 days post-HCT. Diagnosis of CDI and other post-
transplant outcome data were identified through the elec-
tronic database and confirmed with subsequent chart
review. Study activities were approved by the Fred
Hutchinson Cancer Research Center (FHCRC) Institu-
tional Review Board, and participants provided written
informed consent to collect and analyze data for research
purposes according the principles of the Declaration of
Helsinki.
All patients who received an allogeneic HCT at the
FHCRC in Seattle, WA between January 1, 2008–
December 31, 2012 were eligible for inclusion in this





























































Fig. 1 Algorithm to determine C. difficile infection (CDI) positivity for retrospective analyses, adult and pediatric populations combined. Definitions:
PCR (polymerase chain reaction) for detection of gene tcdB, or both genes tcdA and tcdB; EIA (enzyme immunoassay) for detection of C. difficile GDA
(glutamate dehydrogenase antigen); EIA for detection of toxins A & B; CTA for toxin B (cytotoxicity assay); review of patient’s chart was performed in
order to manually review laboratory results and discharge/interim records
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test for C. difficile toxin A or B or genes tcdA or
tcdB within 8 weeks prior to transplantation [26], were
excluded from analysis to avoid misclassification of
Table 1 Patient demographics, by transplanting hospital
Pediatric transplants Adult transplants
Characteristic (n= 192) (n= 990)
Age (yr) – median (IQR) 11 (6, 15) 52 (42, 61)
Sex: male – n (%) 104 (54) 583 (59)
Race/Ethnicity – n (%)
Caucasian 101 (53) 761 (77)
Hispanic 31 (17) 27 (3)
Asian Pacific-Islander 19 (10) 59 (6)
Black 6 (3) 17 (2)
Native American 2 (1) 8 (1)
Other 22 (12) 53 (5)
Unknown 11 (6) 65 (7)
Underlying Disease – n (%)
ALL 67 (35) 107 (11)
AML 34 (18) 341 (34)
MDS 12 (6) 206 (21)
NHL 7 (4) 107 (11)
CML 6 (3) 36 (4)
HD 1 (1) 30 (3)
Other 65 (34) 163 (17)
Stem cell source – n (%)
Bone marrow 102 (53) 155 (16)
PBSC 36 (19) 743 (75)
Cord blood 54 (28) 92 (9)
Donor – n (%)
Sibling 52 (27) 300 (30)
Unrelated 80 (42) 523 (53)
Cord 54 (28) 92 (9)
Haploidentical 6 (3) 68 (7)
Conditioning regimen – n (%)
Myeloablative 175 (91) 559 (57)
Nonmyeloablative 17 (9) 431 (44)
GVHD prophylaxis – n (%)
CSP or FK506, with MTX 106 (55) 360 (36)
MMF regimen 74 (39) 539 (54)
Other/none 12 (6) 91 (9)
Inpatient daysa – median (IQR) 41 (31, 55) 18 (5, 28)
Abbreviations: IQR (interquartile range), ALL (acute lymphoblastic leukemia), AML
(acute myeloid leukemia),MDS (myelodysplastic syndrome), NHL (non-Hodgkin
lymphoma), CML (chronic myeloid leukemia), HD (Hodgkin’s lymphoma), PBSC
(peripheral blood stem cells), GVHD (graft-versus-host disease), CSP (cyclosporine),
FK506 (tacrolimus),MTX (methotrexate),MMF (mycophenolate mofetil)
aWhile under observation (i.e. prior to censorship)
recurrent CDI events as incident cases. In addition,
infants under one year of age were excluded.
Transplant standards, antimicrobial prophylaxis, and
surveillance
Patients received acyclovir or valacyclovir prophy-
laxis for prevention of herpes simplex viruses and
varicella-zoster virus; cord blood transplant recipients
after June 2008 received high-dose valacyclovir for
cytomegalovirus (CMV) prevention [27]. Most patients
received daily fluconazole as antifungal prophylaxis;
those with known or presumptive fungal infections
received either voriconazole, posaconazole or liposo-
mal amphotericin B. All patients received standard
Pneumocystis jirovecii prophylaxis with trimethoprim-
sulfamethaxazole, dapsone, or atovaquone following
engraftment. Screening and preemptive therapy for CMV
have been described elsewhere [27, 28]. Conditioning for
HCT, as well as prophylaxis and treatment of GVHD,
were performed using current standardized protocols
[29]. Acute GVHD was graded according to standard
criteria [30].
All adult patients who developed neutropenia (abso-
lute neutrophil count <500/μl) received levofloxacin pro-
phylaxis until neutrophil recovery. All pediatric patients
under the age of 18 and adults with allergy/intolerance
to levofloxacin received ceftazidime for neutropenic pro-
phylaxis. Adult patients who developed neutropenic fever
underwent routine blood culture testing and adults
preferentially received ceftazidime as first line therapy,
whereas children received either cefepime or a car-
bapenem. Gram-positive coverage with vancomycin was
generally only used for patients with severe mucositis
or those with documented or suspected gram positive
infections. Decisions regarding continuation of therapy,
changes in antibiotic coverage, and clinical and laboratory
assessment of fever were made by the primary care team.
Definitions
Transplanting hospital
Adults patients were hospitalized at the University of
Washington Medical Center (UWMC). Children (<18
years) and few young adults (≥18 years) received inpatient
care at Seattle Children’s Hospital (SCH). Both adults and
children had outpatient care at the Seattle Cancer Care
Alliance ambulatory clinic. All analyses were conducted
separately by the site of transplant. For brevity, patients
transplanted at the pediatric hospital will heretofore be
referred to as ‘pediatric(s)’ or ‘children’ and those at the
adult hospital as ‘adult(s).’
C. difficile testing
C. difficile testing was ordered at the discretion of the pri-
mary team when patients developed new onset diarrhea.
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Table 2 Summary statistics for C. difficile infection (CDI) within 100-days post-allogeneic transplant, per transplanting hospital
Pediatric transplants Adult transplants
Variable (n= 192) (n= 990)
Outcomes – n (%)
CDI 33 (17) 107 (11)
Death 8 (4) 93 (9)
Lost to follow-up 0 (0) 1 (0)
Second transplant 0 (0) 11 (1)
No event 151 (79) 778 (79)
CDI incidence, per 10000 patient-days 20 12
CDI incidence, per transplant year – n (%)
2008 4 (10) 17 (9)
2009 4 (10) 25 (12)
2010 5 (16) 23 (13)
2011 7 (17) 19 (9)
2012 13 (35) 23 (12)
Days to first CDI test – median (IQR) 22 (10, 58) 15 (5, 33)
Days to first positive test for CDI – median (IQR) 51 (5, 72) 16 (5, 49)
Positive tests / all tests (%) 33/125 (26.4) 107/1,308 (8.2)
Probability of testing while inpatienta 1.10 % 4.50 %
Probability of CDI while inpatienta 0.30 % 0.30 %
aPer inpatient day
Per national guidelines, C. difficile testing was performed
only on liquid stool [31]. Repeat testing following a posi-
tive test (“test-of-cure”) was actively discouraged in adult
transplants, but was often performed in inpatient pedi-
atric transplants for removal from inpatient isolation.
During the study observation period, various testing
methods were employed throughout the FHCRC net-
work. Adult transplants: Before 2010, C. difficile test-
ing was performed using EIA (enzyme immunoassay)
tests for both C. difficile GDH (glutamate dehydroge-
nase antigen) (C. Diff Quik Chek by TechLab; Blackburg,
VA) and C. difficile toxins A and B (Toxin A/B Quik
Chek by TechLab, Blackburg, VA). Any specimens test-
ing GDH positive and toxin negative were subjected to
additional testing with a real-time PCR test for the tcdB
gene (laboratory-developed test). CTA (cytotoxin assay)
for toxin B detection was also conducted at physician dis-
cretion [32]. Beginning in 2010, EIA and CTA testing was
replaced center-wide with a standalone PCR test for the
tcdB gene (Xpert C. difficile by Cepheid, Sunnyvale, CA).
Pediatric transplants: C. difficile testing included a com-
bined test for GDH and toxins A and B (C. Diff Quik Chek
Complete by TechLab, Blackburg, VA); if found GDH pos-
itive and toxin negative, a real-time PCR test for toxins A
and B (laboratory-developed) was conducted.
For the purposes of this study, CDI was defined as a sin-
gle instance of liquid stool found positive for C. difficile
toxins A or B, tcdA gene, or tcdB gene. Figure 1 depicts
the algorithm used for both adult and pediatric transplant
populations to determine CDI in this study.
Statistical analyses
The association between potential risk factors (age, year
of transplant, stem-cell source, conditioning regimen, and
GVHD prophylactic regimen) and CDI risk were ana-
lyzed through both univariate and backward-eliminated
(variable inclusion threshold of p < 0.1) cause-specific
multivariate Cox proportional hazards models, where
observation time was censored at 100 days, death, re-
transplant, or lost to follow-up. Additionally, onset of
overall GVHD (grades≥ II), GI GVHD (grades≥ II), and
inpatient acquisition (i.e. exposure to inpatient stay 3
days prior) were analyzed in a similar manner and were
modeled as time-dependent variables. Multilevel indi-
cator variables were first tested for global significance,
and if found significant, individual levels were tested
against the reference group for significance. Cumulative
incidence functions were derived from the subdistribu-
tion hazard functions and plotted for each transplant-
ing hospital (pediatric/adult), where death was treated
as a competing risk. Yearly proportions of patients
tested and diagnosed with C. difficile via any method
(EIA/CTA/PCR) versus PCR were calculated. Statistical
significance was defined at p ≤ .05. Data analyses were
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Fig. 2 Comparison of 100-day post-allogeneic cumulative incidence curves between pediatric and adult transplants: a Incidence of C. difficile
testing; b Incidence of CDI. Figure 2(a) displays the cumulative proportion of patients tested for C. difficile, and Fig. 2(b) displays cumulative
incidence plots depicting the progression of C. difficile infection incidence over time. Note: Scales of graphs 2(a) and 2(b) differ
conducted using Stata version 13.1 (StataCorp; College
Station, TX).
Results and discussion
A total of 1240 allogeneic HCT recipients transplanted
between 2008 through 2012 were eligible for inclusion
in this study. Due to pre-transplant CDI, 58 patients (11
pediatrics and 47 adults) were excluded from primary
analyses. Therefore, 1182 patients comprised the final
study population, including 192 pediatric and 990 adult
HCT recipients (Table 1). Pediatric and adult HCT recip-
ients differed by graft type, as bone marrow (53 %) and
cord blood (28 %) were the most common graft types
transplanted among children, and peripheral blood stem
cells (PBSC) were most commonly transplanted among
adults (75 %). Myeloablative conditioning was signifi-
cantly more frequent in children (91 %) than in adults
(57 %, p < .0001).
Thirty-three pediatric patients (17 %) developed a CDI
episode at a median of 51 days (interquartile range
[IQR]= 5, 72) after HCT for an incidence rate of 20 per
10,000 patient-days, compared with 107 adults (11 %) at a
median of 16 days (IQR= 5, 49) for an incidence rate of
12 per 10,000 patient-days (Table 2). Figure 2 shows the
cumulative proportion of patients tested for C. difficile (a)
and the cumulative incidence of CDI (b).
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Fig. 3 Comparison of yearly 100-day post-allogeneic cumulative incidence curves for CDI: a Pediatric Transplants; b Adult Transplants. Note: Scales
of graphs 3(a) and 3(b) differ
Yearly proportions of patients diagnosed with CDI were
assessed for each site (Table 2; Fig. 3). Diarrhea leading to
testing was common in both groups, but adults appeared
to experience more testing for C. difficile (Fig. 4). Com-
pared to 2008, pediatric HCT recipients experienced an
increased risk of CDI in 2012 (HR= 4.0, p= .02). This
increase appeared independent of yearly variations in PCR
testing (Fig. 4). In contrast, none of the yearly cumu-
lative incidences were significantly different from 2008
among adults, despite widespread testing in this group
and a transition to standalone PCR testing in 2010 (Fig. 4).
Among those diagnosed with CDI during our study, the
median days to diagnosis suggested that adults were diag-
nosed earlier than children (16 days [IQR: 5, 49] vs. 51 days
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Fig. 4 Proportion of pediatric patients tested positive per testing method (any vs. PCR) per year of transplant: a Pediatric Transplants; b Adult
Transplants. C. difficile test includes any of the following tests: EIA (toxins A & B), CTA, or PCR (tcdA or tcdB gene). Dark bars indicated any C. difficile
test, grey bars indicate those patients tested by PCR only. Colored lines (pink and blue) indicated percentage of positive results by testing type
[IQR: 5, 72]; Table 2). Prior to diagnosis, all pediatric CDI
cases were inpatient at some point during observation,
contrary to adult CDI cases (Fig. 5).
In univariate analyses of the pediatric population, inpa-
tient stay in the 3 days prior was significantly associated
with an increase in CDI risk (HR= 1.8, p= .03; Table 3),
although this variable was no longer significant in the
multivariate model. In addition, year of transplant was a
significant risk factor for pediatric CDI in both univariate
and multivariate models, with year 2012 associated with 4
times the CDI risk of 2008 (HR= 4.0, p= .02; adjusted HR
[aHR]= 4.0, p= .02). In univariate analyses of the adult
patients, myeloablative transplantation significantly pre-
dicted CDI, while advanced age significantly decreased
CDI risk. However, myeloablative transplant remained the
sole significant risk factor for CDI in the multivariate
model (HR= 1.8, p= .005; aHR= 1.8, p= .005).
Apparent differences in the timing and incidence of
CDI between adult and pediatric recipients around day
50 post-HCT (Fig. 2) prompted an additional analysis
that focused on the possibility of increased C. difficile
acquisition among pediatric patients staying in a large,
independently-owned outpatient housing facility. This
facility was utilized by multiple pediatric families, includ-
ing a large number of non-transplant patients. Although
transplant patients resided in individual apartments in a
separate section of the structure, other areas within the
building (e.g. playrooms, common rooms) were available
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Fig. 5 Inpatient time exposure after allogeneic HCT per each CDI case: a Pediatric Transplants, b Adult Transplants. Plotted longitudinal bars indicate
inpatient and outpatient time over first 100 days until C. difficile event by type of transplant (5[a] = Pediatric, 5[b]= Adult) in patients with
documented C. difficile infection
for use for anyone within the facility. Using admittance
and discharge records, time contributed in the pediatric
outpatient housing facility was determined. Location of
CDI acquisition was defined as location (inpatient, outpa-
tient facility housing, or outpatient elsewhere) of each CDI
case 3 days pre-diagnosis [26]. Hazard estimates did not
show a significant change in pediatric CDI acquisition risk
from the outpatient housing facility compared to acquisi-
tion from other locations (outpatient facility housing vs.
inpatient: HR= 0.67, p= .45; outpatient facility housing
vs. outpatient elsewhere: HR= 2.16, p= .22). However,
unlike other outpatient facilities, review of this facility’s
infection control practices identified limited use of bleach
in terminal room cleaning.
Conclusions
This study of allogeneic HCT recipients demonstrated
that children and adults are at high risk for CDI dur-
ing the early (1–100 days) post-transplant period. Within
this post-transplant timeframe, 11 % of adults and 17 %
of children developed incident CDI. Diarrhea leading to
C. difficile testing was common within the entire cohort
but more widespread among adults. Among adult HCT
recipients, only myeloablative conditioning was found to
be associated with an increased risk for CDI. Our analyses
detected year 2012 as the sole predictor for CDI among
pediatric patients. In neither population did increases in
PCR testing appear to influence the incidence of CDI.
Reported CDI incidence estimates in allogeneic HCT
recipients vary between 2–27 % [7–16]. Variations in
follow-up time, cohort size, the inclusion of autologous
recipients or the inclusion of pre-transplant cases may
have contributed to differences in reported incidence esti-
mates. As HCT patients have demonstrated a high risk
of CDI recurrence [12, 13], the inclusion of patients with
preexisting CDI may also inflate incidence estimates. Fur-
thermore, the routine application of PCR testing may
contribute to higher rates of C. difficile [31, 33, 34]. While
the 2010 transition to standalone PCR testing in our adult
transplant patients did not appear to increase CDI inci-
dence, this finding may have resulted from incorporation
of PCR into the prior multistep testing protocols.
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Table 3 Univariate and multivariate Cox proportional hazards models for CDI post-allogeneic HCT, per transplanting hospital
Pediatric transplants (n= 192) Adult transplants (n= 990)
Univariate Multivariate Univariate Multivariate
Variable HR p HR p HR p HR p
Age group (yr) .5




<60 – Ref. .04 –
60+ 0.6
Year of transplant .03 .03 .42
2008 Ref. Ref. Ref.
2009 0.9 0.9 1.5 –
2010 1.6 1.6 1.6
2011 1.7 1.7 1
2012 4 4 1.5
Stem cell source .32 .13
Bone marrow Ref. – Ref. –
PBSC 1.9 0.6
Cord blood 1.2 0.8
GVHD prophylaxis .06 .13
CSP or FK506, with MTX Ref. – Ref. –
MMF regimen 0.9 0.7
Other/none 3.1 1.1
Conditioning regimen .57 .005 .005
Nonmyeloablative Ref. – Ref. Ref.
Myeloablative 1.5 1.8 1.8
Overall GVHDa .24 .34
Grades 0–I Ref. – Ref. –
Grades II–IV 1.1 1.3
Gut GVHDa .6 .83
Grades 0–I Ref. – Ref. –
Grades II–IV 0.6 0.9
Inpatient acquisitionb 1.7 .02 – 2.1 .12 –
Abbreviations: PBSC (peripheral blood stem cells), GVHD (graft-versus-host disease), CSP (cyclosporine), FK506 (tacrolimus),MTX (methotrexate),MMF (mycophenolate mofetil),
aGVHD onset modeled as time-dependent
bdefined as inpatient stay within 3 days prior to the day of observation
Variations in CDI incidence across studies may also
reflect differences in pre-transplant asymptomatic C. dif-
ficile colonization. Diarrhea is extremely common in HCT
and frequently leads to C. difficile testing, as seen in our
study. With such frequent testing, asymptomatic C. diffi-
cile can be misidentified as true CDI [10, 15]. However,
it is also true that patients with asymptomatic coloniza-
tion can progress to symptomatic infection [10, 15, 17, 35].
Colonization rates could not be determined in our cohort,
although the number of early CDI events suggests that
pre-transplant colonization may have contributed to adult
post-transplant CDI; the role of colonization in pediatric
HCT is unknown and requires additional study.
Two prior analyses [8, 9] have linked GVHD (over-
all or GI) with CDI. However, the directionality of this
association is unclear, as GVHD precedes CDI in some
individuals and follows CDI in others [35]. One study
accounting for this directionality found that overall/GI
GVHD significantly predicted the development of CDI
between 2 months to one year post-transplant [12]. Our
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results found that neither overall GVHD nor GI GVHD
(grades ≥2) significantly predicted subsequent CDI. We
may have seen similar associations had we observed our
patients beyond 100 days.
Pediatric HCT recipients may experience increased
opportunities for nosocomial transmission, as children in
our center tend to spend more time inpatient than adults.
Exposure to other children and fomites (e.g. toys) may
facilitate C. difficile within pediatric facilities, particu-
larly since asymptomatic colonized children may act as
C. difficile reservoirs [22–25] and have previously been
linked to transmission [36, 37]. Despite evidence sug-
gesting CDI risk is unique in pediatrics, many published
studies do not discern between pediatric and adult HCT
recipients. Smaller retrospective studies of pediatric allo-
geneic HCT recipients have reported lower incidence
estimates (9 % [38] and 13 % [11]) than the 17 % observed
in our study. One prospective study performed weekly
surveillance cultures and found a similar incidence to our
study, with 16 % of pediatric allogeneic recipients found
positive (irrespective of stool consistency) [39].
None of the HCT-associated risk factors evaluated in
our study predicted CDI in children. Although calendar
year 2012 did predict increased pediatric CDI incidence,
pediatric testing practices were consistent during the
study, suggesting that other unmeasured factors may be
responsible for such changes. When late post-transplant
incidence in pediatric HCT recipients prompted an eval-
uation of CDI acquisition at an independent outpatient
facility, our analysis found no statistical associations.
However, we did identify areas of improvement, most
notably the addition of bleach to terminal cleaning at
this facility. These findings provide a reminder to assure
best practices for infection control in outpatient residen-
tial facilities and care centers geared toward pediatric
populations [40].
Unfortunately, we were limited in our ability assess fre-
quency of outpatient visits, or the duration and type of
antibiotic use. Therefore, incidence and risk differences
between pediatric and adult patients were not tested for
statistical significance due to the presence of these poten-
tial confounders. Although ours is the largest study to
address CDI in pediatric transplant patients, the limited
size of our pediatric population still restricted our ability
to detect associations of smaller magnitudes. Further-
more, as is typical with studies of HCT patients, many
aspects of the transplant experience are not independent
of one another, allowing for opportunities for possible
co-linearity during multivariate risk factor analyses.
In conclusion, our study provides data on CDI inci-
dence and risk factors among both pediatric and adult
patients after allogeneic HCT. While our study provides
further confirmation that both populations are at high
risk of CDI during the first 100 days post-transplant,
the implementation of standalone PCR testing did not
appear to increase the rate of CDI diagnosis at our cen-
ter. Differences in CDI risk between adults and children,
as previously observed in non-transplant populations and
suggested by our study, support the differentiation of
adults from children when assessing post-transplant CDI.
Due to small numbers of pediatric HCT recipients at
most centers, future multicenter studies assessing CDI
incidence in this population are needed.
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